HHS Adds New Members to Vaccine Advisory Panel Amid Legal and Market Uncertainty 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
OpenAI Faces Scrutiny After Banning ChatGPT Account of Tumbler Ridge Shooting Suspect 
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand 
USITC to Review Impact of Revoking China’s PNTR Status, Potentially Raising Tariffs on Chinese Imports 
Lynas Rare Earths Shares Surge on Strong Half-Year Earnings and Rising Global Demand 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Anthropic Refuses Pentagon Request to Remove AI Safeguards Amid Defense Contract Dispute 
Netflix Stock Jumps 14% After Exiting Warner Bros Deal as Paramount Seals $110 Billion Acquisition 
Trump Imposes Temporary 10% Global Tariff After Supreme Court Blocks Earlier Trade Duties 
Star Entertainment Secures Debt Refinancing Deal with WhiteHawk Capital to Boost Liquidity 
U.S. Imposes Steep Countervailing Duties on Solar Imports from India, Indonesia and Laos 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Israel Declares State of Emergency as Iran Launches Missile Attacks 
Trump Raises Tariffs to 15% Under Section 122 After Supreme Court Ruling 
FERC Approves Blackstone Infrastructure’s Acquisition of TXNM Energy, Advancing Utility Merger 
Hims & Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a warning from the U.S. Food and Drug Administration, which said it would take action against the telehealth company over its $49 weight-loss medication. The decision marks a significant shift for the fast-growing digital health provider as regulatory scrutiny around compounded weight-loss drugs continues to intensify.
The compounded semaglutide pill had been marketed as a more affordable alternative to brand-name GLP-1 weight-loss drugs, which have surged in popularity due to their effectiveness in treating obesity and supporting metabolic health. By offering the pill through its telehealth platform, Hims & Hers aimed to expand access for patients who were unable to obtain or afford FDA-approved injectable versions. However, the FDA has made it clear that compounded versions of semaglutide raise safety and compliance concerns, particularly when they are promoted outside of strict regulatory allowances.
In its statement, Hims & Hers emphasized that patient safety and regulatory compliance remain top priorities. The company said it would work to align its offerings with FDA guidance while continuing to provide other weight-management services and treatments through its platform. This move reflects the growing pressure on telehealth providers to ensure that compounded medications are used only in limited, legally permitted circumstances, such as during officially recognized drug shortages.
The FDA’s stance signals a broader effort to rein in telehealth companies that have rapidly entered the weight-loss market by offering lower-cost alternatives to popular obesity drugs. As demand for semaglutide-based treatments remains strong, regulators are increasingly focused on preventing the widespread distribution of compounded versions that may not meet the same safety and quality standards as approved medications.
For consumers, the development underscores the importance of understanding the differences between FDA-approved drugs and compounded alternatives. As Hims & Hers adjusts its strategy, the company is expected to continue exploring compliant ways to meet demand for weight-loss solutions while navigating an evolving regulatory landscape that is reshaping the future of telehealth and obesity treatment.
